Metallibure

Metallibure
Clinical data
Trade names	Aimax, Suisynchron, Turisynchron
Other names	Methallibure; Methallibur; ICI-33828; AY-61122; NSC-69536
Drug class	Antigonadotropin
Identifiers
	IUPAC name 1-but-3-en-2-yl-3-(methylcarbamothioylamino)thiourea;
CAS Number	926-93-2;
PubChem CID	3003791;
ChemSpider	2274191;
UNII	MBU5XJ97C4;
CompTox Dashboard (EPA)	DTXSID70862475 ;
ECHA InfoCard	100.011.952
Chemical and physical data
Formula	C7H14N4S2
Molar mass	218.34 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C=C)NC(=S)NNC(=S)NC;
	InChI InChI=1S/C7H14N4S2/c1-4-5(2)9-7(13)11-10-6(12)8-3/h4-5H,1H2,2-3H3,(H2,8,10,12)(H2,9,11,13); Key:CGFFKDRVHZIQHL-UHFFFAOYSA-N;

Metallibure (INNTooltip International Nonproprietary Name) (brand names Aimax, Suisynchron, Turisynchron; former developmental code names ICI-33828, AY-61122, NSC-69536), also known as methallibure (USANTooltip United States Adopted Name, BANTooltip British Approved Name) or methallibur (German), is a medication which was introduced in 1973 and has been used in veterinary medicine to synchronize estrus.^[1]^[2] It was withdrawn in the United States and Europe due to teratogenicity and has been replaced with altrenogest (Regumate, Matrix), a progestin.^[2]^[3]

The precise mechanism of action of metallibure is unknown.^[2] It has been described as a "nonsteroidal antigonadotropin" and it appears to act directly on the pituitary gland and/or hypothalamus to suppress gonadotropin secretion.^[2] However, metallibure has also been reported to be an antiprogestogen and to act specifically via inhibition of the biosynthesis or secretion of progesterone.^[4]

Metallibure has similar endocrinological effects in women.^[5] It is associated with several unpleasant side effects including appetite loss, nausea, occasional vomiting, lethargy, and drowsiness.^[5] Animal toxicity studies revealed that the medication induced the development of cataracts, and this resulted in the termination of its clinical development.^[5]

References

^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 781–. ISBN 978-1-4757-2085-3.
^ ^a ^b ^c ^d I. Gordon (22 October 2013). Controlled Breeding in Farm Animals. Elsevier. pp. 313–. ISBN 978-1-4832-8569-6.
^ Brüssow KP, Schneider F, Kanitz W, Rátky J, Kauffold J, Wähner M (2009). "Studies on fixed-time ovulation induction in the pig". Soc Reprod Fertil Suppl. 66: 187–95. PMID 19848281.
^ A. Labhart (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 523–. ISBN 978-3-642-96158-8.
^ ^a ^b ^c JUCKER (21 December 2013). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Birkhäuser. pp. 102–. ISBN 978-3-0348-7065-8.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

[Elks2014-1] J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 781–. ISBN 978-1-4757-2085-3.

[Gordon2013-2] I. Gordon (22 October 2013). Controlled Breeding in Farm Animals. Elsevier. pp. 313–. ISBN 978-1-4832-8569-6.

[pmid19848281-3] Brüssow KP, Schneider F, Kanitz W, Rátky J, Kauffold J, Wähner M (2009). "Studies on fixed-time ovulation induction in the pig". Soc Reprod Fertil Suppl. 66: 187–95. PMID 19848281.

[Labhart2012-4] A. Labhart (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 523–. ISBN 978-3-642-96158-8.

[JUCKER2013-5] JUCKER (21 December 2013). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Birkhäuser. pp. 102–. ISBN 978-3-0348-7065-8.

[1]

[2]

[3]

[4]

[5]

See also

References